Ruxolitinib for Premalignant Breast Disease

NCT02928978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Ductal Carcinoma In Situ
Atypical Lobular Hyperplasia
Atypical Ductal Hyperplasia
Lobular Carcinoma In Situ

Interventions

DRUG: Ruxolitinib
DRUG: Placebo (for Ruxolitinib)

Sponsor

Julie Nangia

Collaborators

[object Object]
[object Object]